Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Enzymatica AB

Market Cap 602M 527M 487M 454M 852M 56.99B 860M 5.78B 2.25B 27.97B 2.26B 2.21B 97.24B P/E 2024
-5.73x
P/E 2025 -8.89x
Enterprise Value 570M 499M 461M 430M 807M 53.95B 814M 5.47B 2.13B 26.48B 2.14B 2.09B 92.06B EV / Sales 2024
5.88x
EV / Sales 2025 7.96x
Free-Float
56.66%
Yield 2024 *
-
Yield 2025 -
1 day-1.59%
1 week-1.59%
Current month-9.16%
1 month+4.64%
3 months+8.30%
6 months+50.30%
Current year+30.53%
1 week 2.41
Extreme 2.41
2.6
1 month 2.35
Extreme 2.35
2.93
Current year 1.6
Extreme 1.6
3.4
1 year 1.6
Extreme 1.6
3.4
3 years 1.34
Extreme 1.34
5.45
5 years 1.34
Extreme 1.34
13.4
10 years 1.34
Extreme 1.34
24.7
Manager TitleAgeSince
Chief Executive Officer - 01/02/2026
Chief Operating Officer 61 01/01/2011
Director of Finance/CFO - 13/04/2026
Director TitleAgeSince
Chairman 58 15/02/2016
Chairman 64 19/12/2016
Director/Board Member 71 19/12/2016
Date Insider Type Main position Quantity % Market Cap.
04-01Sell

Responsable ventes & marketing

40,000 0.0165%
12-30Buy

Chairman

20,000 0.0082%
12-27Buy

Chairman

20,000 0.0082%
Change 5-day change 1-year change 3-year change Capi.($)
-1.59%-1.59%-11.74%-8.49% 63.85M
+0.32%-2.73%+44.49%+143.28% 980B
+1.27%-3.98%+54.41%+41.13% 550B
+6.25%+1.00%+24.13%+68.06% 382B
+0.25%-3.09%+23.33%+16.78% 316B
+0.42%-1.28%+27.89%+14.71% 272B
+1.67%-1.47%+26.76%+32.88% 268B
+2.39%+4.42%-36.96%-45.12% 199B
+2.11%-2.95%+19.14%+51.83% 182B
+0.90%-0.57%+15.09%+60.89% 154B
Average +1.23%-2.43%+18.65%+37.60% 330.24B
Weighted average by Cap. +1.22%-3.50%+31.28%+65.69%

Financials

2024 2025
Net sales 45.58M 39.89M 36.86M 34.4M 64.53M 4.31B 65.12M 438M 170M 2.12B 171M 167M 7.36B 53.9M 47.17M 43.59M 40.69M 76.33M 5.1B 77.02M 518M 201M 2.5B 202M 198M 8.71B
Net income -53.18M -46.54M -43.01M -40.14M -75.3M -5.03B -75.99M -511M -198M -2.47B -200M -195M -8.59B -51.89M -45.41M -41.97M -39.17M -73.48M -4.91B -74.15M -498M -194M -2.41B -195M -191M -8.38B
Net Debt -73.01M -63.9M -59.05M -55.11M -103M -6.91B -104M -701M -272M -3.39B -274M -268M -11.79B -32.11M -28.1M -25.97M -24.24M -45.47M -3.04B -45.88M -308M -120M -1.49B -121M -118M -5.19B
Logo Enzymatica AB
Enzymatica AB (publ) is a Sweden-based life science company that develops and sells medical devices for infection-related diseases. The Company deals with research, development and sales of products based on enzyme technology and related activities. Enzymatica AB (publ) develops solutions that support the body's own defenses against virus, irritants and microorganisms. The Company offers products which are based on a barrier technology, includes marine enzymes. Enzymatica AB (publ) focuses on product development based on the tested and patented barrier technology used in the common cold product ColdZyme, a mouth spray that protects against colds, can help shorten the duration of the cold if used in the early stages of infection, relieves cold symptoms, and soothes sore throats.
Employees
21
Date Price Change Volume
22/06/26 2.480 kr -1.59% 36,198
18/06/26 2.520 kr +0.80% 125,420
17/06/26 2.500 kr -0.40% 43,593
16/06/26 2.510 kr -3.46% 84,343

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ENZY Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!